ViewRay is highlighting clinical results from a phase II trial that explored the efficacy of delivering ablative doses of radiation to pancreatic cancer patients at the American Society for Radiation Oncology (ASTRO) annual meeting in San Antonio.
Presenter Dr. Parag Parikh of Henry Ford Cancer Institute in Detroit, MI, shared results from the
Stereotactic MRI-Guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer trial, which included 136 patients treated with ViewRay's ablative MRIdian SMART at 13 centers around the world at 50 Gy in five fractions.
The primary outcome of the trial was whether patients had grade 3 or higher gastrointestinal toxicity in the first 90 days after SMART treatment, and the researchers found no incidences of this.
The trial's secondary measures were overall survival, local control, and distant progression-free survival. Parikh and colleagues found the following:
- 93.9% one-year overall survival from diagnosis
- 82.9% one-year local control
- 50.6% distant progression-free survival
"Ablative SMART for locally advanced and borderline resectable pancreatic cancer is safe and is promising to improve patient outcomes in this devastating disease," Parikh said in an October 24 ViewRay statement.
